Finch Therapeutics Group マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Matt Blischak

最高経営責任者

US$775.7k

報酬総額

CEO給与比率	32.5%
CEO在任期間	1.5yrs
CEOの所有権	n/a
経営陣の平均在職期間	1.5yrs
取締役会の平均在任期間	6.2yrs

経営陣の近況

Recent updates

Finch to cut workforce by about 37% after Takeda ends bowel disease collaboration

Sep 01

Finch to get back rights to IBD product candidates after Takeda ends collaboration

Aug 25

Finch Therapeutics GAAP EPS of -$0.48 misses by $0.07, revenue of $0.36M

Aug 11

Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation

Mar 15

Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation

Dec 15

We Think Finch Therapeutics Group (NASDAQ:FNCH) Needs To Drive Business Growth Carefully

Aug 28

Finch Therapeutics: Gut Instinct Says Buy

Jun 14

CEO報酬分析

Finch Therapeutics Group の収益と比較して、Matt Blischak の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-US$14m
Mar 31 2024	n/a	n/a	-US$16m
Dec 31 2023	US$776k	US$252k	-US$75m

報酬と市場: Mattの総報酬 ($USD 775.65K ) は、 US市場 ($USD 652.28K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Mattの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Matt Blischak (61 yo)

1.5yrs

在職期間

US$775,651

報酬

Mr. Matthew P. Blischak, also known as Matt, JD, serves as Chief Executive Officer of Finch Therapeutics Group, Inc. since May 16, 2023 and serves as its President & Secretary since May 2023. He has intell...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Matthew Blischak	President	1.5yrs	US$775.65k	データなし
Lance Thibault	Chief Financial Officer	1.5yrs	US$168.79k	データなし
James Sigler	Executive Vice President of CMC	6.8yrs	データなし	データなし

1.5yrs

平均在職期間

61yo

平均年齢

経験豊富な経営陣: FNCHの経営陣は経験豊富とはみなされません ( 1.5年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Jeffery Smisek	Independent Director	7.8yrs	US$2.29k	2.63% $ 483.8k
Chris Shumway	Independent Director	4.2yrs	US$2.29k	26.24% $ 4.8m
Christian Lange	Independent Chair	7.2yrs	US$2.29k	0% $ 0
Domenic Ferrante	Independent Director	5.2yrs	US$2.29k	1.32% $ 242.8k

6.2yrs

平均在職期間

58yo

平均年齢

経験豊富なボード: FNCHの取締役会は経験豊富であると考えられます ( 6.2年の平均在任期間)。

Finch Therapeutics Group マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Finch Therapeutics Group, Inc. Announces Resignation of Joseph Vittiglio as Chief Business and Legal Officer and Secretary, Effective December 31, 2022

High number of new directors

Finch Therapeutics Group, Inc. Announces Executive Appointments

High number of new directors

Key Executive recently bought US$12m worth of stock

Recent updates

Finch Therapeutics Files Form 15

Finch Therapeutics to Delist Its Common Stock from the Nasdaq Global Select Market on or About October 31, 2024 and Announces SEC Deregistration

Finch Therapeutics Group, Inc.(OTCPK:FNCH) dropped from NASDAQ Composite Index

Finch Therapeutics Group Receives the Delisting Letter from the Office of the General Counsel of Nasdaq Notifying the Listing Panel Determines to Delist the Company from Nasdaq

Nasdaq Listing Qualifications Department Issues an Additional Staff Determination to Finch Therapeutics Group for Continued Non-Compliance with the Market Value of Publicly Held Shares Rule

Finch Therapeutics Receives Notice from Nasdaq Regarding Non-Compliance with the Requirements of Nasdaq Listing Rule 5605(c)(2)

The Nasdaq Stock Market LLC Notifies Finch Therapeutics Regarding Company’s Status as 'Public Shell'

Finch Therapeutics Group Receives Non-Compliance Notice from Nasdaq

New major risk - Share price stability

Finch Therapeutics Announces 1-for-30 Reverse Stock Split of Common Stock to Satisfy the Minimum Price Requirement for Continued Listing on the Nasdaq Global Select Market

First quarter 2023 earnings released: US$1.33 loss per share (vs US$0.52 loss in 1Q 2022)

Finch Therapeutics Group, Inc. Reports Unaudited Consolidated Impairment of Long-Lived Assets for the First Quarter Ended March 31, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Finch Therapeutics Group, Inc. Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets

Finch Therapeutics Group, Inc. Announces Resignation of Joseph Vittiglio as Chief Business and Legal Officer and Secretary, Effective December 31, 2022

Price target decreased to US$12.00

Finch Therapeutics Group, Inc. Plans to Reduce its Workforce by Approximately 37%

Finch to cut workforce by about 37% after Takeda ends bowel disease collaboration

Finch to get back rights to IBD product candidates after Takeda ends collaboration

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Finch Therapeutics GAAP EPS of -$0.48 misses by $0.07, revenue of $0.36M

High number of new directors

Finch Therapeutics Group, Inc.(NasdaqGS:FNCH) dropped from Russell 2500 Value Index

Finch Therapeutics Announces Workforce Restructuring to Focus Resources on Key Development Programs

Price target decreased to US$27.67

Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation

Finch Therapeutics Group, Inc. Pauses Enrollment in PRISM4 Its Phase 3 Clinical Trial of CP101 in Recurrent C. Difficile Infection

Finch Therapeutics Group, Inc. Announces Executive Appointments

Finch Therapeutics Group, Inc. Announces U.S. Patent and Trademark Office Grants Two New Patents for FIN-211

High number of new directors

Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation

Third quarter 2021 earnings released: US$0.21 loss per share

We Think Finch Therapeutics Group (NASDAQ:FNCH) Needs To Drive Business Growth Carefully

Finch Therapeutics: Gut Instinct Says Buy

Key Executive recently bought US$12m worth of stock

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24